Eli Lilly stock slips after Novo Nordisk trims 2025 forecast; Jaypirca meets endpoint in CLL trial against J&J's Imbruvica, ...

Shares of Eli Lilly & Co. erased gains to trade down nearly 1% after White House press secretary Karoline Leavitt said the company was among 17 drugmakers that will be receiving letters from President ...

Shares of global pharmaceutical company Eli Lilly (NYSE:LLY) fell 4.3% in the morning session after its key competitor in the ...

Eli Lilly (LLY) has recently shared positive developments in its innovative therapies, reporting significant progress with ...

Shares of Eli Lilly and Company (NYSE:LLY) dropped Thursday morning after the company announced that its diabetes treatment ...

The company's stock closed more than 6% lower on Wednesday. Eli Lilly now expects full-year adjusted earnings of between $13.02 and $13.52 per share, down from previous guidance of $16.10 to $16. ...

Eli Lilly (LLY) is one of the stocks most watched by Zacks.com visitors lately. So, it might be a good idea to review some of the factors that might affect the near-term performance of the stock.

Eli Lilly ( LLY 0.64%) has been one of the best-performing pharmaceutical leaders in the past five years. Thanks to strong ...

Eli Lilly (NYSE: LLY) has been on fire over the past two years. The drugmaker has generated excellent financial results and delivered strong market performance -- so strong that detractors might ...

Eli Lilly (LLY) has recently been on Zacks.com's list of the most searched stocks. Therefore, you might want to consider some ...

Eli Lilly (NYSE: LLY) has been on fire over the past two years. The drugmaker has generated excellent financial results and delivered strong market performance -- so strong that detractors might ...